Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
Academic rigor, journalistic flair
Articles on Prescription drugs
Displaying 1 - 20 of 69 articles
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
The proposed plans will likely benefit patients – but only if more is done to ensure pharmacists can provide these additional services.
Don’t be intimidated by the package insert that comes with your medication. Learning how to read it can help you better understand how drugs work.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
It is illegal to share prescription drugs with friends and family.
Prescription opiods, stimulants such as those used to treat ADHD and the ingredients found in sexual dysfunction drugs like Viagra are some of the drugs that are being marketed to US consumers.
About 1 in 4 Americans with diabetes who need insulin struggle to pay for this lifesaving drug.
Products aimed at sexual dysfunction and weight loss were the most common dietary supplements that contained hidden – and potentially harmful – ingredients.
Canada lags behind other developed countries in access to newer antimicrobials. Here’s why that matters, and what can be done about it.
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
Tylenol has long been considered a go-to medication for low to moderate pain and for fever reduction, even during pregnancy. But mounting evidence suggests that it is unsafe for fetal development.
Energy drinks and coffee both contain lots of caffeine. That’s a problem for teens, especially those who take prescription stimulants.
Ending the opioid epidemic requires addressing not only treatment gaps in addiction and overdose, but also inadequate pain management.
Resistant bacteria aren’t the only risk posed by overprescribing antibiotics. A more immediate risk is side-effects and reactions, which a new review shows are surprisingly frequent and often severe.
From expanding children’s coverage to reducing surprise bills, Biden and lawmakers may be able to broaden health care access.
When news reports tout a drug, people get interested, even if the benefits are unproven. Patient hopes, requests and demands can easily turn into real prescriptions in their doctor’s office.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
To implement pharmacare, the Liberals will need to negotiate with the provinces, and the mostly Conservative premiers are unlikely to make this easy. The insurance industry also has much to lose.
When codeine became a prescription only drug in 2018, the number of overdoses dropped, our new research shows. But restricting sales of codeine is only one way to reduce harm from opioids.
Top contributors
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor of Pharmacy Practice, University of Connecticut
-
Associate Professor of Public Health, Texas A&M University
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Associate Professor, Political Science, McMaster University
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Professor, School of Population and Public Health, University of British Columbia
-
Associate professor, School of Public Health, University of Alberta
-
Professor of Criminal Law, University of Sydney
-
Senior research fellow, Monash University
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Honorary Fellow, Department of Health Sciences, University of York
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Lecturer in Criminology, University of Auckland
-
Professor of Health Economics, Queen's University Belfast
